2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …
F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome
K Kimura, T Kimura, M Ishihara, Y Nakagawa… - Circulation …, 2019 - jstage.jst.go.jp
Acute coronary syndromes (ACS) are a comprehensive disease concept characterized by
acute myocardial ischemia caused by disruption of coronary artery plaque and consequent …
acute myocardial ischemia caused by disruption of coronary artery plaque and consequent …
[HTML][HTML] Dapagliflozin and cardiovascular outcomes in type 2 diabetes
SD Wiviott, I Raz, MP Bonaca… - … England Journal of …, 2019 - Mass Medical Soc
Background The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–
glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is …
glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is …
Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017
M Kinoshita, K Yokote, H Arai, M Iida… - … of atherosclerosis and …, 2018 - jstage.jst.go.jp
Every 5 years, the JAS publishes guidelines for the treatment of dyslipidemia and
atherosclerosis. To date, this society has released four such guidelines. Since 2007, the JAS …
atherosclerosis. To date, this society has released four such guidelines. Since 2007, the JAS …
Heart disease and stroke statistics—2017 update: a report from the American Heart Association
Summary Each year, the American Heart Association (AHA), in conjunction with the Centers
for Disease Control and Prevention, the National Institutes of Health, and other government …
for Disease Control and Prevention, the National Institutes of Health, and other government …
Ferroptosis is involved in diabetes myocardial ischemia/reperfusion injury through endoplasmic reticulum stress
W Li, W Li, Y Leng, Y Xiong, Z Xia - DNA and cell biology, 2020 - liebertpub.com
Myocardial ischemic disease affects the prognosis in perioperative patients. Diabetes can
aggravate myocardial injury. The purpose of this research is to investigate the effect of …
aggravate myocardial injury. The purpose of this research is to investigate the effect of …
[PDF][PDF] 2016 European Guidelines on cardiovascular disease prevention in clinical practice
MF Piepoli, AW Hoes, S Agewall… - Polish Heart …, 2016 - journals.viamedica.pl
2.3. 9. Wnioski................................................ 838 2.4. Inne markery ryzyka.......................................
. 840 2.4. 1. Wywiad rodzinny/(epi) genetyka............ 840 2.4. 1.1. Wywiad …
. 840 2.4. 1. Wywiad rodzinny/(epi) genetyka............ 840 2.4. 1.1. Wywiad …
[PDF][PDF] 2016 ESC/EAS guidelines for the management of dyslipidaemias
AL Catapano, I Graham, G De Backer… - Polish Heart …, 2016 - journals.viamedica.pl
5.1. Wpływ stylu życia na stężenie cholesterolu całkowitego i stężenie cholesterolu frakcji
lipoprotein o małej gęstości................................ 1259 5.2. Wpływ stylu życia na stężenie …
lipoprotein o małej gęstości................................ 1259 5.2. Wpływ stylu życia na stężenie …
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new …
Background The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab
reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this …
reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this …
[PDF][PDF] 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
5. Leczenie.............................................................. 1225 5.1. Farmakoterapia
niedokrwienia...................... 1225 5.1. 1. Ogólne leczenie objawowe................. 1225 5.1. 2 …
niedokrwienia...................... 1225 5.1. 1. Ogólne leczenie objawowe................. 1225 5.1. 2 …